Seattle Genetics (SGEN -3.3%) says the European Commission has granted conditional marketing...


Seattle Genetics (SGEN -3.3%) says the European Commission has granted conditional marketing authorization to its collaborator Takeda Pharmaceuticals for two indications of Adcetris. The first is for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma, and the second for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. Under the agreement SGEN will receive two milestone payments from Millennium, one for each indication, totaling $25M.

From other sites
Comments (2)
  • cp3frank
    , contributor
    Comment (1) | Send Message
     
    Great reason for the stock to be down 3%
    31 Oct 2012, 04:43 PM Reply Like
  • jim2703
    , contributor
    Comments (3) | Send Message
     
    This is great news! Has Seagen released its royalty percentage and projected earnings from these international sales?
    31 Oct 2012, 04:43 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs